New Three-Drug cocktail aims to tackle Hard-to-Treat myeloma

NCT ID NCT05560399

Ongoing Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of three drugs—iberdomide (a pill), elotuzumab (given by IV), and dexamethasone—in people whose multiple myeloma has returned or stopped responding to prior treatments. The study is small (up to 37 people) and primarily looks at safety and the best dose, while also checking if the cancer shrinks. It is too early to know if this combo will become a standard therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iberdomide (oral pill) combined with elotuzumab (IV) and dexamethasone (oral or IV)
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
What could go wrong: This is a very early, small study (only 7 participants so far) focused on safety and dosing. It may not show strong benefit, and side effects could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Icahn School of Medicine

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.